Skip to content
Menu

Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.

Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.

Read at benzinga.com

← All stock news